SynthesisFrontiers in pharmacology2025

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review.

Chuang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.